Citigroup maintains Veradermics at Buy, raises price target to $175 from $160
Citigroup kept its Buy rating on Veradermics and increased its price target to $175 from $160, suggesting a 21.6% upside from the Nov 9 close of $143.95. Recent analyst price targets for the company range from $150 to $204.
How this was made

The 30-second read
Why it matters
The upgrade suggests potential upside but lacks fresh operational news, limiting immediate trading impact.
Market read
Analyst price target change provides modest new information for traders monitoring micro‑cap equities.
What to watch
No new fundamental data accompanies the target change; market reaction may be muted.
Background
Citi analyst raised the price target for Veradermics from $160 to $175, indicating a 9.4% increase.
Market effects
None
None
None
Counterpoint
Price target upgrades may be overly optimistic for a micro‑cap with limited liquidity.
Key entities
- CompanyVeradermics
Subject of the analyst price target upgrade.